Story
Amgen, AstraZeneca Report Positive Trial Data for Combination Lung Cancer Therapy
Amgen (NASDAQ:AMGN) and AstraZeneca (LON:AZN) on Tuesday announced positive results from a late-stage clinical trial for a combination drug treatment targeting extensive-stage small-cell lung cancer. The study showed that the therapy improved survival rates for patients, a significant development for the two pharmaceutical giants.
Key Trial Findings
The trial evaluated Amgen's Imdelltra used in conjunction with AstraZeneca’s Imfinzi as a maintenance treatment. This combination was compared against a regimen of Imfinzi used alone in patients whose disease had not progressed after receiving standard initial therapy.
According to the companies' announcement, the combination treatment demonstrated a statistically significant improvement across several key endpoints:
- Overall survival
- Progression-free survival
- Objective response rate
AdThe companies also reported that no new safety concerns were identified during the trial, reinforcing the combination's favorable risk-benefit profile.
Commercial and Strategic Context
Imdelltra is a key oncology asset for Amgen. The drug, which belongs to a class of treatments known as bispecific antibodies that help the body's immune system fight cancer, received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2024, followed by a traditional approval in 2025.
The drug is already a significant revenue contributor, generating $513 million in sales for Amgen last year. The oncology portfolio is a cornerstone of Amgen's business, accounting for approximately 23% of the company's total revenue. These positive trial results could further solidify Imdelltra's position in the competitive lung cancer treatment landscape.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.